Form 4: Mineralys Therapeutics Director, Daphne Karydas, Reports Stock Option Grant
SEC Form 4 Filing
Daphne Karydas, a director of Mineralys Therapeutics, reported the acquisition of stock options.
Summary
- On February 13, 2025, Daphne Karydas, a director of Mineralys Therapeutics, Inc., acquired stock options for 32,900 shares.
- The options have an exercise price of $10.20.
- The stock options vest in 12 substantially equal monthly installments following the grant date.
- The options expire on February 13, 2035.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, and does not contain information that would significantly impact sentiment positively or negatively.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders.
Stakeholder Impact
- The stock option grant could incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of the stock option grant and earliest transaction. |
| 02/13/2035 | Expiration date of the stock options. |
| 02/24/2025 | Date of the Form 4 filing. |
Keywords
stock options, director, Mineralys Therapeutics, MLYS, Form 4, beneficial ownership, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.